Article
Notable-HCC: A phase Ib trial of neoadjuvant tislelizumab with stereotactic body radiotherapy in patients with early stage resectable hepatocellular carcinoma
2024-01-09
Abstract excerpt
<title>Abstract</title> <p>Background Hepatocellular carcinoma (HCC) is highly invasive, even for early stage HCC, the 1-year post-operative recurrence rates were over a quarter; so far no standard neoadjuvant therapy (NAT) is recommended by major guidelines. NAT with immune checkpoint inhibitors (ICIs) has been tried in varying solid tumors including HCC; radiotherapy showed immuno-modulating effect in the trea...
Topics
Open a Topic to create a Post that cites this publication.
Identifiers and source
- Literature Corpus work
- f1319382-1eb9-514c-a8f8-216f902d3436
- DOI
- 10.21203/rs.3.rs-3823003/v1
